Barclays’s RayzeBio, Inc. Common Stock RYZB Stock Holding History

Barclays’s Portfolio RYZB Stock Details RYZB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-35,016	Closed	-$2.18M	–	5467
2023 Q4	$2.18M	Buy	+35,016	New	+$870K	﹤0.01%	2852

Barclays's RYZB Position: Q1 2024 in Review

Barclays sold out of RayzeBio, Inc. Common Stock (RYZB) in Q1 2024, closing a stake of 35,016 shares — an estimated $2.18M sold.

Barclays first reported a position in RYZB in Q4 2023 and held it in 1 quarter. The position peaked at $2.18M in Q4 2023. 0 funds tracked by Wall St. Rank hold RYZB as of Q1 2024.

Barclays reported no remaining RayzeBio, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Barclays sold 35,016 RayzeBio, Inc. Common Stock shares in Q1 2024, an estimated $2.18M.
Barclays first reported a position in RayzeBio, Inc. Common Stock in Q4 2023 and held it in 1 quarter.
Barclays's RayzeBio, Inc. Common Stock position peaked at $2.18M in Q4 2023.
0 funds tracked by Wall St. Rank held RayzeBio, Inc. Common Stock as of Q1 2024.

Based on Barclays's 13F filing for Q1 2024, filed 15 May 2024.